Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 14,500 shares, a drop of 19.4% from the September 15th total of 18,000 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 7,500 shares, the days-to-cover ratio is presently 1.9 days.

Analyst Upgrades and Downgrades

Separately, Benchmark restated a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research note on Tuesday, October 1st.

Anebulo Pharmaceuticals Stock Performance

NASDAQ ANEB opened at $1.83 on Tuesday. The company has a market capitalization of $47.46 million, a PE ratio of -4.95 and a beta of -1.01. Anebulo Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $3.30. The company has a 50-day simple moving average of $1.97 and a 200 day simple moving average of $2.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.08. As a group, analysts forecast that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.